Subscribe To Our Free Newsletter |
Cipla receives USFDA approval for Lanreotide Injection
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (lanreotide) Injection and is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs).